GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Dividend Yield %

NKGen Biotech (NKGen Biotech) Dividend Yield % : 0.00% (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Dividend Yield %?

As of today (2024-05-26), the Trailing Annual Dividend Yield of NKGen Biotech is 0.00%.

The historical rank and industry rank for NKGen Biotech's Dividend Yield % or its related term are showing as below:

NKGN's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.485
* Ranked among companies with meaningful Dividend Yield % only.

NKGen Biotech's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.

As of today (2024-05-26), the Forward Dividend Yield % of NKGen Biotech is 0.00%.

NKGen Biotech's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


NKGen Biotech Dividend Yield % Historical Data

The historical data trend for NKGen Biotech's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Dividend Yield % Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Dividend Yield %
- - -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Dividend Yield % Get a 7-Day Free Trial - - - - -

Competitive Comparison of NKGen Biotech's Dividend Yield %

For the Biotechnology subindustry, NKGen Biotech's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NKGen Biotech's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's Dividend Yield % falls into.



NKGen Biotech Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


NKGen Biotech  (NAS:NKGN) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


NKGen Biotech Dividend Yield % Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.